A generic alternative indicated for Men's Health and Oncology Support. This clinical formulation prevents androgen hormones from binding to receptors, slowing cellular growth in targeted tissues.
Indicated to address prostate cancer growth by targeting androgen receptors to alleviate disease progression and support clinical management in male patients with advanced conditions.
Mechanism of Action
Bicalutamide blocks the androgen receptors on the surface of prostate cancer cells. This prevents testosterone from attaching to and stimulating these cells, which slows down or stops the tumor's growth.
Route of Administration
Oral
Onset Time
Steady state in 1 month
Duration
24 hours
Contraindications
Hypersensitivity to bicalutamide, Pregnancy, Female patients (for cancer)
Severe Adverse Events
Liver failure, Severe lung disease, Heart failure, Severe allergic reactions, Photosensitivity
Common Side Effects
Hot flashes, Breast tenderness
Uncommon Side Effects
Breast enlargement, Nausea, Fatigue, Joint pain, Constipation, Weakness
Information for Bicalutamide is sourced from established medical standards and updated frequently. It is provided for general reference and should be confirmed with a healthcare professional before use.
